<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Interactive diabetes case 17: A 47-year-old patient with newly discovered type 2 diabetes – A3
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Interactive diabetes case 17: A 47-year-old patient with newly discovered type 2 diabetes – A3
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Interactive diabetes case 17: A 47-year-old patient with newly discovered type 2 diabetes – A3
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Lloyd Axelrod, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Dec 19, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          ANSWER
         </span>
         <span class="headingEndMark">
          —
         </span>
         Incorrect.
        </p>
        <p>
         Sulfonylureas are effective agents for the treatment of newly diagnosed type 2 diabetes but are not indicated as initial pharmacologic therapy. (See
         <a class="medical medical_review" href="/z/d/html/1779.html" rel="external">
          "Initial management of hyperglycemia in adults with type 2 diabetes mellitus"
         </a>
         .)
        </p>
        <p>
         Sulfonylureas reduce the glycated hemoglobin (A1C) to an extent comparable with
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         , approximately 1.5 percent, but are associated with a weight gain of approximately 2 kg. Sulfonylureas carry the risk of hypoglycemia, especially the longer-lasting agents in older adults, although episodes of severe hypoglycemia (requiring the help of someone else) are infrequent. Among second-generation sulfonylureas (the preferred group of agents),
         <a class="drug drug_general" data-topicid="8494" href="/z/d/drug information/8494.html" rel="external">
          glyburide
         </a>
         is more likely to cause hypoglycemia than
         <a class="drug drug_general" data-topicid="8492" href="/z/d/drug information/8492.html" rel="external">
          glipizide
         </a>
         or
         <a class="drug drug_general" data-topicid="8491" href="/z/d/drug information/8491.html" rel="external">
          glimepiride
         </a>
         and is not the preferred agent in this class. Glyburide should not be used in patients with renal insufficiency (a serum creatinine &gt;1.5 mg/dL in men or &gt;1.4 mg/dL in women) because of the increased risk of hypoglycemia. Glipizide is preferred in this setting. (See
         <a class="medical medical_review" href="/z/d/html/1786.html" rel="external">
          "Sulfonylureas and meglitinides in the treatment of type 2 diabetes mellitus"
         </a>
         .)
        </p>
        <p>
         In a patient with a contraindication to
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         because of preexistent gastrointestinal disease, or in a patient who does not tolerate a careful trial of metformin, a sulfonylurea such as
         <a class="drug drug_general" data-topicid="8492" href="/z/d/drug information/8492.html" rel="external">
          glipizide
         </a>
         is a reasonable alternative. While sulfonylureas are not the first choice for pharmacologic therapy of newly diagnosed diabetes, an agent in this class may have a role as an additional medication in patients who are not well controlled with one drug, usually metformin. (See
         <a class="medical medical_review" href="/z/d/html/1790.html" rel="external">
          "Management of persistent hyperglycemia in type 2 diabetes mellitus"
         </a>
         .)
        </p>
        <p>
         Return to the beginning to try again. (See
         <a class="medical medical_review" href="/z/d/html/4207.html" rel="external">
          "Interactive diabetes case 17: A 47-year-old patient with newly discovered type 2 diabetes"
         </a>
         .)
        </p>
       </div>
       <div id="topicVersionRevision">
        Topic 4247 Version 8.0
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
